)
NEWS
Media Contacts:
Seqirus news releases
Seqirus news releases
Seqirus Applauds the Executive Order to Accelerate Enhanced Protection Against Influenza Threats
The Executive Order represents a significant step towards accelerating access to more effective technologies, such as cell-based platforms, immunity-enhancing adjuvants, and other innovative approaches.
Seqirus opens new Centre of Excellence in Amsterdam
New laboratory and office space will enhance influenza vaccine research and development and help the company prepare for Brexit.
Seqirus and Laboratoire Arrow sign Distribution Agreement in France
This news release is intended for Health Professional media only.
Seqirus starts on time delivery of flu vaccines to support NHS immunisation programmes across the UK
This news release is intended for Health Professional media only.
Seqirus Presents New Scientific Data Comparing Circulating Influenza B Viruses With Both Cell-Based and Egg-Based Influenza B Reference Viruses
Seqirus, a global leader in influenza prevention, today presented new scientific data at the Options for the Control of Influenza (OPTIONS X) Conference in Singapore that demonstrated circulating influenza B/Victoria (B/Vic) viruses are a closer match to cell-based B/Vic vaccine viruses compared with egg-based B/Vic vaccine viruses.